Evaluation of the Pharmacokinetics and Safety of ABT-493 and ABT-530 in Subjects With Normal and Impaired Renal Function
Phase of Trial: Phase I
Latest Information Update: 15 Nov 2016
At a glance
- Drugs Glecaprevir (Primary) ; Pibrentasvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Pharmacokinetics
- Sponsors AbbVie
- 17 Apr 2016 Results presented at The International Liver Congres 2016.
- 18 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 17 Dec 2015 Planned end date changed from 1 Oct 2015 to 1 Jan 2016, as reported by ClinicalTrials.gov.